Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Importance of Defense Strategies
- What Does Pharma Stand to Lose?
- Overview of Potential Strategies
- Company-Based Strategies
- Mergers
- Increase Emphasis on Biotech R&D
- Improved Productivity and Reduced Risk Through Contract Research
- Acquisition of a Generics Company
- Product-Based Strategies
- Additional Patents
- New Isomers or Enantiomers
- Modifi ed-Release Versions and Alternative Delivery Methods
- Combination Products
- New Indications/Switch to Over-the-Counter Promotion
- Litigation
- Prospects for Success in the Courts
- Authorized Generics Strategy
- Is It Better to Litigate or Settle?
- A Useful Short-Term Strategy
- Challenges to the Authorized Generics Strategy
- European Strategies
- Outlook
Tables
- 1. Sales of the Four Largest Domestic Generics Manufacturers in Japan,
Fiscal Year Ended March 2006
- 2. Select Generics Defense Strategies
- 3. Generics Companies Bulk Up, 2006
- 4. Product-Specifi c Defense Strategies
- 5. Branded Drugs Authorized as Generics in 2006
Figure
- 1. Worldwide Share of Generics Market by Value of Sales, 2006
- 2. Blockbusters Facing Patent Expiry in 2007 (with 2006 Worldwide Sales)
- 3. New Chemical Entity (NCE) Launches, 1990-2005
- 4. Approvals of New Biopharmaceutical Products in the United States, 1990
Through October 2006
- 5. Ideal Timeline for Extending a Product' s Lifecycle
- 6. Authorized Generics Agreements, 1998-2006
|
Related Report
|
View Cart
